Cagrilintide and semaglutide are often mentioned together, and for good reason: they act through different hormone systems and have been combined in trials rather than pitted against each other. Cagrilintide is a long-acting amylin analog and is investigational, while semaglutide is a GLP-1 receptor agonist that is FDA-approved and widely used. An honest comparison has to note that in Novo Nordisk's Phase 3 program the two are studied as a fixed combination called CagriSema, so they are frequently partners, not just alternatives.
Reviewed for accuracy · Last reviewed July 8, 2026The framing that matters most here is that these two are not really rivals. In the Phase 3 REDEFINE program they are combined into a single once-weekly injection (CagriSema) using 2.4 mg of each, on the reasoning that hitting the amylin and GLP-1 pathways together may affect appetite more than either alone. So the honest headline is that they are studied as partners.
On regulatory status they differ clearly. Semaglutide is FDA-approved for type 2 diabetes and weight management with a defined label and titration, while cagrilintide is investigational with no approved product or prescribing dose, whether alone or in the combination. That difference in evidence footing is the practical dividing line.
Because cagrilintide's monotherapy data comes from a Phase 2 trial and semaglutide's from Phase 3 trials and a product label, the two are not on comparable evidence, and the data does not support ranking one above the other for any individual. Both report predominantly gastrointestinal side effects. Which, if anything, is appropriate is a medical decision.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.